PharmaMar presents results at EORTC-NCI-AACR to highlight a pipeline of targeted therapies

PharmaMar will present data at the EORTC-NCI-AACR for its drug Yondelis and several investigational compounds, highlighting its pipeline of targeted therapies. Some of the most relevant results showed will focus on the mechanism of action of Aplidin, a drug that is currently in clinical trials for the treatment of multiple myeloma, and the activity of a new antibody-drug conjugate on HER-2 positive tumor cells and xenograft tumors. —> Read More Here


Leave a Reply

Your email address will not be published. Required fields are marked *